

STIC Biotechnology Systems Branch

1FW16

CRF Problem Report

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) experienced a problem when processing the following computer readable form (CRF):

Application Serial Number: 09/927,006A
Filing Date: 8/09/01
Date Processed by STIC: 5/4/06

STIC Contact: Mark Spencer: Telephone: 571-272-2510; Fax: 571-273-0221

Nature of CRF Problem:

- ☐ (circle one) Damaged or Unreadable (for Unreadable, see attached)
- ☐ Blank (no files on CRF) (see attached)
- ☐ Empty file (filename present, but no bytes in file) (see attached)
- ☐ Wrong file saved to CRF (invention title, docket number, or applicant(s) do not match those in official application) (see attached)
- ☐ Not saved in ASCII text
- ☐ Sequence Listing was embedded in the file. According to Sequence Rules, submitted file should **only** be the Sequence Listing.
- ☒ Did not contain a Sequence Listing. (see attached sample)
- ☐ Other:

**PLEASE USE THE CHECKER VERSION 4.4.0 PROGRAM TO REDUCE ERRORS.
SEE BELOW FOR ADDRESS:**

<http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm>

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. **Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05):**
U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street, Alexandria, VA 22314

Revised 01/20/06

09/927,006A

5/4/08

IFW16

Amino Acid Sequence Listing for Application Serial No. 09/927,006
titled ANTI-ANGIOGENIC PEPTIDES FOR CANCER TREATMENT filed on Aug. 9, 2003

SEQ ID NO: 1: Ile-Val-Pro-Ser-Leu-Gly-Pro-Pro-Ser-Glu-Gln-Asp

SEQ ID NO: 2: Met-Phe-Gly-Asn-Gly-Lys-Gly-Tyr-Arg-Gly-Lys-Lys-Ala-Thr-Thr-Val-
Thr-Gly-Thr-Pro

SEQ ID NO: 3: Gln-Gln-Trp-Ala-Ala-Gln-Glu-Pro-His-Arg-His-Ser-Thr-Phe-Ile-Pro-
Gly-Thr-Asn-Lys-Trp-Ala-Gly-Leu-Glu-Lys-Asn-Tyr

SEQ ID NO: 4: Arg-Asn-Pro-Asp-Gly-Asp-Ile-Asn-Gly-Pro-Trp

(sample of submitted file)

This is an invalid format for a sequence listing.

Please 1) Consult Sequence Rules for valid format.
2) Consult sample Sequence Listing
(attached)

<110> Smith, John; Smithgene Inc.

<120> Example of a Sequence Listing

<130> 01-00001

<140> PCT/EP98/00001

<141> 1998-12-31

<150> US 08/999,999

<151> 1997-10-15

<160> 4

<170> PatentIn version 2.0

<210> 1

<211> 389

<212> DNA

<213> Paramecium sp.

<220>

<221> CDS

<222> (279)...(389)

<300>

<301> Doe, Richard

<302> Isolation and Characterization of a Gene Encoding a
Protease from Paramecium sp.

<303> Journal of Genes

<304> 1

<305> 4

<306> 1-7

<307> 1988-06-31

<308> 123456

<309> 1988-06-31

<400> 1

| | | | | | | |
|------------|------------|------------|------------|------------|------------|-----|
| agctgtagtc | attcctgtgt | cctcttctct | ctgggcttct | caccctgcta | atcagatctc | 60 |
| aggagagagt | tcttgaccct | cctctgcctt | tgcagcttca | caggcaggca | ggcaggcagc | 120 |
| tgatgtggca | attgctggca | gtgccacagg | cttttcagcc | aggcttaggg | tgggttccgc | 180 |
| cgcggcgcgg | cggccccctc | cgcgctcctc | tgcgcctct | ctctcgctct | cctctcgctc | 240 |

Consult this

ggacctgatt aggtgagcag gaggaggggg cagtttagc atg gtt tca atg ttc agc 296
Met Val Ser Met Phe Ser
1 5

ttg tct ttc aaa tgg cct gga ttt tgt ttg ttt gtt tgt ttg ttc caa 344
Leu Ser Phe Lys Trp Pro Gly Phe Cys Leu Phe Val Cys Leu Phe Gln
10 15 20

tgt ccc aaa gtc ctc ccc tgt cac tca tca ctg cag ccg aat ctt 389
Cys Pro Lys Val Leu Pro Cys His Ser Ser Leu Gln Pro Asn Leu
25 30 35

<210> 2
<211> 37
<212> PRT
<213> Paramecium sp.

<400> 2
Met Val Ser Met Phe Ser Leu Ser Phe Lys Trp Pro Gly Phe Cys Leu
1 5 10 15

Phe Val Cys Leu Phe Gln Cys Pro Lys Val Leu Pro Cys His Ser Ser
20 25 30

Leu Gln Pro Asn Leu
35

<210> 3
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Designed peptide based on size and polarity to act as a linker between the alpha and beta chains of Protein XYZ.

<400> 3
Met Val Asn Leu Glu Pro Met His Thr Glu Ile
1 5 10

<210> 4
<400> 4
000

identifiers and their accompanying information as shown in the following table. The numeric identifier shall be used only in the "Sequence Listing." The order and presentation of the items of information in the "Sequence Listing" shall conform to the arrangement given below. Each item of information shall begin on a new line and shall begin with the numeric identifier enclosed in angle brackets as shown. The submission of those items of information designated with an "M" is mandatory. The submission of those items of information designated with an "O" is optional. Numeric identifiers <110> through <170> shall only be set forth at the beginning of the "Sequence Listing." The following table illustrates the numeric identifiers.

| Numeric Identifier | Definition | Comments and Format | Mandatory (M) or Optional (O) |
|--------------------|-------------------------------|---|--|
| <110> | Applicant | Preferably max. of 10 names; one name per line; preferable format: Surname, Other Names and/or Initials | M |
| <120> | Title of Invention | | M |
| <130> | File Reference | Personal file reference | M when filed prior to assignment of appl. number |
| <140> | Current Application Number | Specify as: US 07/999,999 or PCT/US96/99999 | M, if available |
| <141> | Current Filing Date | Specify as: yyyy-mm-dd | M, if available |
| <150> | Prior Application Number | Specify as: US 07/999,999 or PCT/US96/99999 | M, if applicable include priority documents under 35 USC 119 and 120 |
| <151> | Prior Application Filing Date | Specify as: yyyy-mm-dd | M, if applicable |
| <160> | Number of SEQ ID NOs | Count includes total number of SEQ ID NOs | M |
| <170> | Software | Name of software used to create the Sequence Listing | O |
| <210> | SEQ ID NO: #: | Response shall be an integer representing the SEQ ID NO shown | M |
| <211> | Length | Respond with an integer expressing the number of bases or amino acid residues | M |

6

| | | | |
|-------|----------|--|--|
| <212> | Type | Whether presented sequence molecule is DNA, RNA, or PRT (protein). If a nucleotide sequence contains both DNA and RNA fragments, the type shall be "DNA." In addition, the combined DNA/RNA molecule shall be further described in the <220> to <223> feature section. | M |
| <213> | Organism | Scientific name, i.e. Genus/species, Unknown or Artificial Sequence... In addition, the "Unknown" or "Artificial Sequence" organisms shall be further described in the <220> to <223> feature section. | M |
| <220> | Feature | Leave blank after <220>. <221-223> provide for a description of points of biological significance in the sequence. | M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA. |
| <221> | Name/Key | Provide appropriate identifier for feature, preferably from WIPO Standard ST.25 (1998), Appendix 2, Tables 5 and 6 | M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence |
| <222> | Location | Specify location within sequence; where appropriate state number of first and last bases/amino acids | M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified |

| | | in feature | base was used in a sequence |
|-------|---------------------------|--|---|
| <223> | Other Information | Other relevant information; four lines maximum | M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA. |
| <300> | Publication Information | Leave blank after <300> | O |
| <301> | Authors | Preferably max of ten named authors of publication; specify one name per line; preferable format: Surname, Other Names and/or Initials | O |
| <302> | Title | | O |
| <303> | Journal | | O |
| <304> | Volume | | O |
| <305> | Issue | | O |
| <306> | Pages | | O |
| <307> | Date | Journal date on which data published; specify as yyyy-mm-dd, MMM-yyyy or Season-yyyy | O |
| <308> | Database Accession Number | Accession number assigned by database including database name | O |
| <309> | Database Entry Date | Date of entry in database; specify as yyyy-mm-dd or MMM-yyyy | O |
| <310> | Patent Document Number | Document number; for patent-type citations only. Specify as, for example, US 07/999,999 | O |

8

| | | | |
|-------|-----------------------|--|---|
| <311> | Patent Filing Date | Document filing date, for patent- type citations only; specify as yyyy-mm-dd | O |
| <312> | Publication Date | Document publication date, for patent-type citations only; specify as yyyy-mm-dd | O |
| <313> | Relevant Residues | FROM (position) TO (position) | O |
| <400> | Sequence | SEQ ID NO should follow the numeric identifier and should appear on the line pre- ceding the actual sequence | M |

5. Section 1.824 is revised to read as follows:

1.824 Form and format for nucleotide and/or amino acid sequence submissions in computer readable form.

(a) The computer readable form required by 1.821(e) shall meet the following specifications:

(1) The computer readable form shall contain a single "Sequence Listing" as either a diskette, series of diskettes, or other permissible media outlined in paragraph (c) of this section.

(2) The "Sequence Listing" in paragraph (a) (1) of this section shall be submitted in American Standard Code for Information Interchange (ASCII) text. No other formats shall be allowed.

(3) The computer readable form may be created by any means, such as word processors, nucleotide/amino acid sequence editors or other custom computer programs; however, it shall conform to all specifications detailed in this section.

(4) File compression is acceptable when using diskette media, so long as the compressed file is in a self-extracting format that will decompress on one of the systems described in paragraph (b) of this section.

(5) Page numbering shall not appear within the computer readable form version of the "Sequence Listing" file.

(6) All computer readable forms shall have a label permanently affixed thereto on which has been hand-printed or typed: the name of the applicant, the title of the invention, the date on which the data were recorded on the computer readable form, the operating system used, a reference number, and an application serial number and filing date, if known.

(b) Computer readable form submissions must meet these format requirements:

(1) Computer: IBM PC/XT/AT, or compatibles, or Apple Macintosh;

(2) Operating System: MS-DOS, Unix or Macintosh;